Sponsor: Ocular Therapeutix
Study Drug: Sustained-release Tyrosine Kinase Inhibitor (Intravitreal Injection)
Control Arm: Afibercept, 50 years old.
Inclusion & Exclusion Criteria: BCVA-20/80 or better in study eye; 20/200 or better in fellow eye
CST: < 500um Other: Sponsor covers fellow eye treatment (any drug)
Join Treatment Naïve & Previously Wet AMD Study
Participating in research gives you access to potential new treatments while contributing to the future of eye care.
Current Studies & Trials
If you have Wet AMD, Dry AMD (Geographic Atrophy), Diabetic Macular Edema, or Retinal Vein Occlusion, you may qualify for a clinical trial. Find an enrolling study.
Follow Us On Social
